Pharmos (PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: LLCF who wrote (563)	2/28/1999 10:56:00 AM
From: yosi s	Read Replies (3) of 1386

At present CC can convert at 10% discount to the price 180 days after placement, or 20% premium to market price whichever is lower. If i remember correctly the 180 day price is around 1.70$ - 1.80$. Yet if you add 20% premium to todays price CC is still ahead. In view of recent trading pattern, there is a large seller, out there. Every other days volume is up unloading shares. Yet volume is down. So I think that a lot of people are just sitting on the sideline awaiting Q4 results, and projection of Alrex and Lotemax sales. And most of all HU 211 partner. Initially I thought that no agreement will come forward prior to end of cohort 3 phase 2. Now there is too much activity at Pharmos, they must be very close to a deal . May be a hint with Q4 results... If the terms of HU211 partnering agreement is good, and if Sales of Alrex and Lotemax projects well as well. I expect a very rapid covering os shorts. CC will have to report to SEC if they have kept their shares. yet no such filling; so they must have sold what ever they cover in past. With just under 1 million short, once this financing is done there will be no overhang.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next